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Abstract
There are currently no established radiological parameters that predict response to immunotherapy. We hypothesised that
multiparametric, longitudinal magnetic resonance imaging (MRI) of physiological parameters and pharmacokinetic models
might detect early biological responses to immunotherapy for glioblastoma targeting NG2/CSPG4 with mAb9.2.27
combined with natural killer (NK) cells. Contrast enhanced conventional T1-weighted MRI at 761 and 1762 days post-
treatment failed to detect differences in tumour size between the treatment groups, whereas, follow-up scans at 3 months
demonstrated diminished signal intensity and tumour volume in the surviving NK+mAb9.2.27 treated animals. Notably,
interstitial volume fraction (ve), was significantly increased in the NK+mAb9.2.27 combination therapy group compared
mAb9.2.27 and NK cell monotherapy groups (p = 0.002 and p= 0.017 respectively) in cohort 1 animals treated with 1 million
NK cells. ve was reproducibly increased in the combination NK+mAb9.2.27 compared to NK cell monotherapy in cohort 2
treated with increased dose of 2 million NK cells (p,0.0001), indicating greater cell death induced by NK+mAb9.2.27
treatment. The interstitial volume fraction in the NK monotherapy group was significantly reduced compared to mAb9.2.27
monotherapy (p,0.0001) and untreated controls (p = 0.014) in the cohort 2 animals. NK cells in monotherapy were unable
to kill the U87MG cells that highly expressed class I human leucocyte antigens, and diminished stress ligands for activating
receptors. A significant association between apparent diffusion coefficient (ADC) of water and ve in combination NK+
mAb9.2.27 and NK monotherapy treated tumours was evident, where increased ADC corresponded to reduced ve in both
cases. Collectively, these data support histological measures at end-stage demonstrating diminished tumour cell
proliferation and pronounced apoptosis in the NK+mAb9.2.27 treated tumours compared to the other groups. In
conclusion, ve was the most reliable radiological parameter for detecting response to intralesional NK cellular therapy.
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Introduction
Glioblastoma (GBM) is a highly aggressive brain tumour where
the patients’ median survival is only 14.6 months [1] despite
aggressive multimodal treatment comprising debulking surgery,
temozolomide (TMZ) given concurrently with fractionated radio-
therapy and additional adjuvant TMZ [1]. This dismal prognosis
is partly due to the diffuse infiltrative nature of GBMs that
invariably results in recurrence within 2 cm of the original surgical
margin [2]. Their molecular heterogeneity, the variable disruption
of the blood brain barrier (BBB) and high tumour interstitial
pressure [3] renders GBM therapy resistant and hinders the entry
of cytotoxic agents, including lymphocytes into the tumour.
According to the imaging response criteria for high-grade gliomas,
the RANO (Response Assessment in Neuro-Oncology) criteria [4],
the treatment effect is evaluated based on changes in the solid
tumour size (bi-dimensionally measured in contrast-enhancing
lesions) and not the underlying pathophysiological changes that
may precede changes in morphology. More specified criteria for
evaluating glioblastoma in trials of anti-angiogenic therapy were
recently proposed [5]. However, the main criteria are still based
on the morphological changes detected by magnetic resonance
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imaging (MRI) or computer tomography (CT). Since development
of local therapies that target the aggressive cell types within GBMs
is the benchmark, imaging modalities that can confirm early
treatment efficacy in the tumour bed are highly needed.
We previously demonstrated that GBMs express high levels of
Neuron-glia 2 (NG2), a cell surface chondroitin sulphate
proteoglycan (CSPG4), that confers proliferative [6–8] and
angiogenic potential [7,9,10] and mediates resistance to chemo-
and radiotherapy [11,12]. Consequently, high NG2 expression in
GBM biopsies is prognostic for shorter patient survival [12]. NG2
is aberrantly expressed by several other tumour types [13–15] and
has been shown to mediate their malignant progression [15]. As a
cell surface molecule, with expression restricted to tumour cells,
and mediating an aggressive disease course, NG2 may be a good
target for immunotherapy. In a recent study, we targeted NG2/
CSPG4 with monoclonal antibody 9.2.27 (mAb9.2.27) combined
with in vitro activated natural killer cells (NK) in an intralesional
adoptive cellular immunotherapy approach [16,17]. We demon-
strated that combination NK+mAb9.2.27 treatment converted the
tumour promoting, anti-inflammatory microenvironment to a pro-
inflammatory one mediated by M1-like macrophage/microglia.
NK+mAb9.2.27 treatment diminished tumour growth and pro-
longed animal survival [16].
NK cells are large granular lymphocytes that are involved in
both innate and adaptive immune responses and are highly
cytotoxic against tumour and virus infected cells. Among cytotoxic
lymphocytes, NK cells are the most efficient effectors against
tumours, and are capable of direct killing without prior
immunization [18]. In human, they recognise targets for killing
through ligation of inhibitory killer immunoglobulin like receptors
(KIRs) to class I human leucocyte antigens (HLA), and function-
ally similar systems exist in rats and mice. Ligation of inhibitory
KIRs to their cognate class I HLA ligands, transduces an
inhibitory signal that, in the absence of activating signals, renders
NK cells hyporesponsive [19,20]. NK cells are highly attractive for
GBM treatment because they have been demonstrated to
preferentially kill GBM stem-like cells [21,22]. Moreover, inter-
leukin-2 (IL-2) activated NK cells express high levels of CD16, a
low affinity FccRIII receptor that binds antibody Fc domains to
mediate potent antibody dependent cellular cytotoxicity (ADCC)
of coated target cells.
One of the greatest challenges in developing therapeutic
regimens is the inability to rapidly and objectively assess the
tumour’s physiological responses to treatment in situ. Moreover,
the tumour’s response to therapy in many cases is transient.
Therefore, quantitative measures to characterize cancer progres-
sion are required for differential diagnosis and therapeutic
monitoring. Imaging techniques, such as MRI, permit diagnosis,
non-invasive, longitudinal monitoring of progression and potential
responses to anti-cancer treatment. Discrimination of the bound-
aries between malignant and normal tissue and the evaluation of
cellular heterogeneity in lesions has proven to be a limitation in
conventional MRI. The use of multiparametric, longitudinal MRI
imaging and subsequent data analyses may provide more accurate
information and hence, improved tumour lesion characterisation
[9]. Thus, we aimed to prospectively identify quantifiable
biological parameters by both morphological and physiological
MRI that may reveal clinically relevant, tumour physiological
changes that may be apparent before structural changes are
evident. Dynamic contrast enhanced MRI (DCE MRI) is
increasingly used in oncology to investigate aspects of tumour
microcirculation and to quantify changes during treatment [23].
The Tofts’ model [24] is a two-compartment pharmacokinetic
model, which allows estimation of the transfer constant (Ktrans),
extracellular extravascular volume fraction (ve) and blood plasma
volume fraction (vp). Diffusion weighted MRI (DWI) detects
changes in water mobility and has been applied to deduce the
cellularity of the tumour and thus of treatment response [25,26].
Herein, we combined DCE MRI and DWI with conventional
morphological MR imaging such as T2-weighted, pre- and post-
contrast T1-weighted imaging to identify imaging parameters that
may be useful for detecting early signs of treatment effects. We
hypothesized that early biological changes that correlate with
response to treatment can be detected by physiological MRI
before they are measurable by histology or in conventional MR
images as altered tumour volumes. In order to monitor tumour
progression longitudinally, post-treatment multiparametric MRI
was performed at two time points. We also aimed to investigate
whether the measured ADC values in the tumours associate with
the estimated perfusion parameters such as the extracellular
volume fraction ve since both parameters may provide information
about the tumour matrix and cell density. In this study, ve proved
to be the most reliable parameter for detection of early treatment
effects.
Materials and Methods
Tumour cell culture and flow cytometry characterisation
The U87MG cell line was purchased from the American Type
Culture Collection, (ATCC; Rockville, MA) and was propagated
and fingerprinted as previously described [7,12].
The cells were immunolabelled in a final volume of 100 ml of
FACS buffer (Miltenyi Biotec, Scheelava¨gen, Sweden) with
PCPCY5.5-conjugated anti-nestin (1:20 dilution, 25/NESTIN
clone, BD Biosciences, Trondheim, Norway), PE-conjugated anti-
vimentin (1:20, RV202, BD Biosciences), FITC-conjugated anti-
GFAP (1:25, GA5, eBioscience), ligands for NK cell receptors were
detected using AlexaFluor488-conjugated anti-MICA (1:40,
159227, R&D Systems, UK), APC-conjugated anti-MICB (1:40,
236511, R&D Systems), unconjugated anti-ULBP-1 (1:10,
170818, R&D Systems), unconjugated anti-ULBP-2-5-6 (1:10,
166510, R&D Systems) and unconjugated anti-ULBP-3 (1:10,
166510, R&D Systems) stained with Pacific Orange- conjugated
Fragment of goat anti-mouse-IgG (1:40, Invitrogen) and HLA
molecules were immunolabelled with APC-conjugated anti-HLA-
A,B,C (1:5, G46-2,6, BD Biosciences), PE-conjugated anti-HLA-E
(1:20, 3D12HLA-E, eBioscience), PE-conjugated anti-HLA-G
(1:20, 87G, Biolegend, San Diego, CA) and FITC-conjugated
anti-HLA-DR,DP,DQ (1:5, Tu39, BD Biosciences). V450 Hori-
zon-conjugated IgG1 (1:20, MOPC-21, BD Biosciences), FITC-
conjugated anti-IgG2a (1:20, PPV-04, Immunotools, Friesoythe,
Germany) and FITC-conjugated9 anti-IgG2b (1:20, PLRV219,
Immunotools) were used as isotype controls. All samples were
stained with Live/Dead Fixable Near-IR Dead Cell Stain Kit
(Invitrogen) in order to gate out dead cells. Data analysis was
performed in FACSDiva Software (BD Biosciences).
Animals
8–10 week old immunodeficient nude rats (Han: rnu/rnu
Rowett Nude), of both sexes were included in the study. The
athymic nude rat is deficient of some T-cell subtypes, but has
normal complement and B-cell function [27]. The animals were
bred in an isolation facility at 25uC (55% relative humidity), 12/
12 hr light cycle, in a specific pathogen free environment and
animal husbandry protocols were maintained as previously
described [7]. All animal procedures were performed in accor-
dance with protocols approved by The National Animal Research
Authority (Oslo, Norway). The animals were inspected daily and
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were sacrificed by CO2 inhalation and decapitation when they
developed neurological symptoms such as lethargy and/or
paralysis, neglected grooming, rotational behaviour, and dome
head. The brains were extracted for further analysis.
Acute dissociation of splenocytes, NK cell purification
and implantation
Rat NK cells were purified from spleens of littermates by
negative selection and cultured for 4–5 days in the presence of
1000 U/ml human recombinant IL-2 (R&D Systems) as previ-
ously described [28]. Tumour spheroids (each containing 30,000
cells) [29] were selected under a stereo light microscope and 32
animals were xenografted with 15 U87MG spheroids. The animals
were anaesthetized with subcutaneous injection of Hypnorm-
Dormicum (0.4 ml/kg) – Roche, Indianapolis, USA), the head
secured in a stereotactic frame (Benchmark; Neurolab, St Louis,
MO) and a short longitudinal incision was made in the scalp
exposing the calvarium. A burr-hole was made 1 mm posterior to
the bregma and 3 mm right lateral to the sagittal suture with a
micro-drill with a bit diameter of 2.9 mm. A Hamilton syringe
with inner diameter of 810 mm was introduced to a depth of
2.5 mm below the brain surface, and the spheroids suspended in
10 ml of phosphate buffered saline (PBS) were slowly injected and
the syringe left in place for 3 min before withdrawal. The skin was
closed with an Ethilon 3–0 suture. We treated two cohorts of
animals, and in both cohorts the tumours were allowed to establish
for 3 weeks prior to random assignment to treatment with
phosphate buffered saline (vehicle control), mAb9.2.27, NK cells
(cohort 1: 1 million cells, cohort 2: 2 million cells) or combination
NK+mAb9.2.27 with corresponding amounts of NK cells. In each
cohort, 3–4 animals were included in the treatment groups.
NK cell infusion and convection enhanced delivery of
mAb 9.2.27
1 or 2 million NK cells were suspended in 10 ml of PBS and
infused into the same coordinates as the tumour using a
stereotactic frame prior to infusion of mAb9.2.27. A glass syringe
(model 701, Hamilton, Bonaduz, Switzerland) secured in a
microprocessor-controlled infusion pump (UMP 2–1, World
Precision Instruments, Aston, Stevenage, UK) slowly delivered
the NK cells over 5 minutes. After infusion, the needle was left in
place for approximately 3 min and thereafter slowly retracted and
the skinfolds closed with polyamide surgical thread (monotherapy
NK cells). Otherwise, azide free mAb9.2.27 antibodies (4 mg/ml
in 24% polyethylene glycol) were thereafter administered through
a 26-gauge cannula connected to an osmotic mini pump (Mini-
Osmotic pump model 2001D,Alzet Inc., Mountainview, CA)[16].
The pumps were installed while the animal was still in the
stereotaxic frame, into the same coordinates as the tumour and
NK cells and infused continuously over 24 h by convection
enhanced delivery at a rate of 8 ml/h. The mAb9.2.27 was a
generous gift from Professor Reisfeld (Scripps Institute for Cancer
research, La Jolla, San Diego, CA, USA).
MR imaging
Pre-treatment T1-weighted and T2-weighted scans were
performed 3 weeks after tumour implantation to verify equal
tumour load in the different groups. Post-treatment multipara-
metric MRI was performed at two time points; 762 and 1761
days after treatment on a 7T Bruker Pharmascan (Bruker Biospin,
Ettlingen, Germany), using a 38 mm rat head transmit and receive
volume coil. The rats were anesthetized with 1–2% isoflurane in
1:2 O2/N2, and positioned prone in a dedicated animal bed
heated with recirculating warm water to keep the rat’s body
temperature stable at 37uC. Respiration and body temperature
was monitored throughout the scanning session using BioTrig Life
Monitoring System (Model 1025 Small Animal Monitoring and
Gating System, SA Instruments). The multiparametric MR
imaging protocol included the following scans: (1) T2-weighted
RARE (rapid acquisition relaxation enhancement) sequence with
repetition time (TR) = 2400 ms, echo time (TE) = 40 ms, rare
factor =8, field of view (FOV) =35635 mm2, matrix size =
2566256, resolution =1376137 mm2/pixel, slice thickness of
1.5 mm (eight slices, no gap) and 12 averages, (2) diffusion weighted
EPI (echo planar imaging) sequence with TR=1500 ms, TE=
35 ms, D=15 ms, d=7 ms, b-values in the range of 300–1200 s/
mm2 (300, 500, 800 and 1200 s/mm2) and three orthogonal gradient
diffusion directions, FOV=35635 mm2, matrix size = 1286128,
resolution = 2736273 mm2/pixel, slice thickness of 1.5 mm (eight
slices, no gap) and 10 averages; (3) RARE T1-map with TR=125,
250, 500, 1200, 2500, 5500 and 10 000 ms, TE=12.5 ms, rare
factor = 2, FOV=35635 mm2, matrix size = 1286128, resolu-
tion = 2736273 mm2/pixel, a slice thickness of 1.5 mm (four slices,
no gap), (4) RARE T1-weighted pre-contrast with TR=1300 ms,
TE=8.86 ms, rare factor = 4, FOV=35635 mm2, matrix size =
2566256, resolution = 1376137 mm2/pixel, a slice thickness of
1.5 mm (eight slices, no gap) and 6 averages; (5) RARE T1-
weighted dynamic contrast enhanced (DCE) series with 206
repetitions, TR=200 ms, TE=8.86 ms, rare factor = 4, FOV
=35635 mm2, matrix size = 1286128, resolution = 2736
273 mm2/pixel and a slice thickness of 1.5 mm (four slices, no
gap), scan time 16 min (temporal resolution = 4.8s). In the dynamic
scan, 0.2 mmol/kg Omniscan (gadodiamide, MW 0.58 kDa, GE
Healthcare, Norway) was injected through the tail vein after
acquisition of 20 baseline images. Another dose of gadodiamide was
injected after the dynamic scan and prior to the acquisition of
RARE T1-weighted post-contrast images with imaging parameters
as described for the RARE T1-weighted pre-contrast sequence
above. The total scan time was approximately 90 min including
pilot scans. An additional follow-up MRI was performed on
surviving animals 3 months after treatment start (RARE T2- and
T1-weighted pre- and post-contrast images only).
MR data analysis and quantification
MR data analysis was performed using in-house programs
written in Matlab7.8.0 (The Mathworks, Inc, MA, USA). The data
analysis included only data from animals with successful MRI
scans (N= 3 in NK+mAb9.2.27 group, N= 5 or 6 NK cells only,
N= 5 or 6 in mAb9.2.27 only and N=5 or 6 in controls
respectively for 7 and 17 days post-treatment). At 3 months, only
structural MRI was performed on N=3 surviving animals in
cohort 2 in the NK+mAb9.2.27 combination therapy group. MRI
data were excluded if unsuccessful contrast agent injections or
pronounced movement artefacts were noted. Tumour size was
measured in post-contrast T1-weighted images by manually
drawing regions of interest (ROIs) of the entire volume of the
tumour based on the signal intensity changes after contrast agent
administration. By implementing a two-compartment model as
described by Tofts [24], and using the T1-map from each
individual animal, as well as the arterial input function measured
by McGrath in rats using a contrast agent with the similar kinetic
properties as gadodiamide [3], the transfer constant (Ktrans),
extracellular extravascular volume fraction (ve) and blood plasma
volume fraction (vp) were estimated. We also estimated the area
under the curve at 1 min (AUC1min), which is a model
independent semi-quantitative measure that reflects contrast agent
kinetics determined by a combination of blood flow, volume and
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permeability [24]. All parameters were calculated on a voxel-by-
voxel basis within the tumour volume. ADC maps (apparent
diffusion coefficient) were calculated on a voxel-by-voxel basis
from the diffusion weighted images with different b-values and in
different directions as previously described [30] [31].
Histological examination immunohistochemistry and
quantification
Brains were formalin fixed, paraffin embedded, and every 20th
3–5 mm thick tissue section was collected for further histological
analysis. These sections were stained with haematoxylin and eosin,
and examined under a light microscope. Representative formalin-
fixed, paraffin-embedded sections from each specimen were
deparaffinised, epitope unmasked using the appropriate method
for each antibody and immunohistochemically stained with
various antibodies; anti-MIB-1 (Ki67, 1:100, Dako, Glostrup,
Denmark), using the avidin-biotin-peroxidase complex (Vectas-
tain, Vector Laboratories, Burlingame, CA) method with 3, 30-
Diaminobenzidine (DAB) and H2O2 (DCS, Hamburg, Germany).
The fraction of Ki67 positive against Ki67 negative tumour cells
(Ki67 labelling index) was quantified in five manually and
randomly selected hot spots in microscopic high power fields
(4006magnification) in all animals in the study group using the
NIS-ElementsTM BR 3.1 software, (Nikon Corporation, Tokyo,
Japan). Detection of apoptotic cells was performed with the
terminal deoxynucleotide nick end-labelling (TUNEL) assay
according to the manufacturer’s instructions (Roche Applied
Bioscience, Mannheim Germany). TUNEL-positive cells were
visualised with DAB as chromogen, and the signal intensity of
TUNEL-positive cells was assessed from the whole tumour section
in 1006magnification in all the animals. The threshold level for
pixel intensity was determined on the basis of four TUNEL stained
tumour sections using a Nikon Eclipse 600 microscope. This
threshold level was stored and subsequently applied with identical
microscope settings for scoring of all tumour sections. Immune
positive elements (pixels above threshold) were measured and
expressed as area fraction of the visual field for each tumour
section. The Growth Index (GI) was determined as the mean ratio
of proliferative to apoptotic cells for all tumours in the groups.
Statistical analysis
Immunohistochemistry data for the treatment groups was
analysed using One way analysis of variance (ANOVA) with
Bonferroni post hoc analysis correction for multiple testing in
GraphPad Prism Statistical Software, version 5.0 (GraphPad, La
Jolla, CA, USA). MRI derived parameters (Ktrans, ve, vp,
AUC1 min, ADC and tumour size) were analysed in Stata v13.1
(StataCorp LP, Texas,USA) using linear models with robust
variance estimates adjusted for clustering of rats. Post hoc analysis
and correction for multiple testing was performed using Scheffe’s
adjustment based on the linear model, using the svy-module in
Stata for the analysis. The figures were also based on the marginal
means from the linear model clustered by rat. Statistical analyses
were performed separately on the two cohorts and by combining
the two first time points. Ordinary linear regression was performed
to test for any associations between the MRI derived parameters.
P-values less than 0.05 were considered statistically significant.
Results
Expression of glial markers and NK cell ligands on U87MG
cells
We characterised the U87MG cells for markers of glial cells and
demonstrated that 97.3% dimly expressed glial fibrilliary acidic
protein (GFAP), 96.5% expressed nestin, 88% were vimentin
positive and 10% expressed A2B5 (Figure 1 and Table 1).
Previously we demonstrated that U87MG cells highly express
NG2/CSPG4 [16]. To investigate whether U87MG cells also
express ligands recognised by NK cell receptors, we characterised
expression of class I and non-classical HLA molecules that are
ligands for inhibitory KIRs and demonstrated that nearly all
U87MG cells highly expressed HLA-A, -B,-C (97.4%). Fewer
proportion of cells expressed HLA-G (14%), HLA-DR, DP,DQ
(33.7%), and HLA-E (1.9%), Figure 1 and Table 1). The UL16
binding proteins (ULBPs) 1, 3, 2/5/6 were densely expressed on
the majority of U87MG cells (40.4%, 94.6% and 95.9%,
respectively, Figure 1C and Table 1). In contrast U87MG
expressed low to negligible levels of MICA (7.99%) and MICB
(0.59%) (Figure 1 and Table 1). MICA, MICB and the ULBPs are
all stress induced ligands recognised by NKG2D activating NK
cell receptor (Figure 1 and Table 1). Collectively, these data
indicate that U87MG might be resistant to NK cell lysis.
Morphological tumour progression
T1-weighted post-contrast MR images of rats bearing U87MG
tumours demonstrated contrast enhancement within the tumour
mass in all tumours one week prior to treatment, indicating high
angiogenic capacity and tumour progression (data not shown). Post-
treatment images at 761 and 1762 days revealed increased tumour
volume in all groups in both cohorts, but with a large intra-group
heterogeneity (Figure 2A and Figure 2B). No significant differences
in mean tumour size between treatment groups was found in any of
the cohorts (Figure 2B), Two-way ANOVA, p.0.05. Follow-up
MRI scans performed on the NK+mAb9.2.27 treated animals that
survived 3 months after treatment demonstrated reduction in
tumour volume, where the animals did not have contrast enhancing
tumour tissue left (Figure 2A). The affected areas were detected on
T2-weighted images as oedematous regions with high signal
intensity (Figure 3). Histological analyses at end-stage showed
increased necrosis in the NK+mAb9.2.27 treated tumours com-
pared to the mAb9.2.27 and NK cell monotherapy, as well as
control untreated tumours, (Figure 4A). Tumour cell proliferation
was diminished in the NK+mAb9.2.27 treated tumours (F= 7.4,
p= 0.0039) compared to monotherapy NK cells (t = 4.29, p,0.001)
and stand-alone mAb9.2.27 (t = 3.51, p,0.01), Figure 4A and 4B)
with post-hoc Bonferroni adjusted analyses, after the ANOVA. For
apoptosis the Bonferroni adjusted p-value showed that the NK+
mAb9.2.27 combination treatment significantly promoted tumour
cell death (F= 20, p= 0.0001), Figure 4A and 4C, compared to NK
monotherapy (t = 5.22, p,0.0001), mAb9.2.27 only (t = 6.139, p,
p,0.0001) and untreated controls (t = 5.20, p,0.0001). The growth
index, estimated as the ratio of cell proliferation over apoptosis,
demonstrated reduced tumour growth in the NK+mAb9.2.27
combination treatment group compared to the other groups
(Figure 4D). The NK monotherapy group exhibited the highest
growth index compared to the other groups (Figure 4D). Also, we
found greater tumour infiltration by microglia/macrophages with
pro-inflammatory phenotypes at end-stage in combination therapy
group compared to monotherapy and control groups (Figure S1).
Consequently, combination NK+mAb9.2.27 treatment significantly
prolonged animal survival compared to NK cells and mAb9.2.27
monotherapy as we recently reported [16].
Increased volume fraction in NK+mAb9.2.27 treatment
responsive tumours
DCE MRI detected changes in the tumour physiology earlier
than the structural changes detected with conventional MRI. The
parameter denoting extravascular extracellular volume fraction,
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ve, was significantly increased in the NK+mAb9.2.27 combination
treated animals compared to NK cells monotherapy (Scheffe,
t =23.90, p = 0.017, CI 20.226 to 20.021) and mAb9.2.27
monotherapy (Scheffe, t = 5.32, p= 0.002, CI 0.064 to 0.263) in
cohort 1 animals that were treated with 1 million NK cells,
indicating reduction in cellular burden induced by combination
treatment (Figure 5A). There was a small but not significant
tendency to increased ve in NK+mAb9.2.27 compared to
untreated control (Scheffe, t =23.04, p = 0.068, CI 20.293 to
0.08). These effects were reproducible in treatments with 2 million
NK cells, where NK+mAb9.2.27 combination treatment signifi-
cantly increased ve compared to NK cells monotherapy (Scheffe,
Figure 1. Expression of glial cell markers and NK cell ligands on U87MG tumour cells. (A) Mean Fluorescence Intensity (MFI) histograms
and % cells expressing glial markers (GFAP,Nestin, Vimentin, and A2B5), (B) MFI histograms and % cells expressing class I HLA ligands (HLA-A,-B,-C),
non-classical HLA-G and HLA-E, as well as HLA-DR,DP,DQ. (C) MFI histograms and % cells expressing ULBP 1, 3, 2/5/6, MICA and MICB activating
ligands. Dark histograms represent negative control, light histograms represent stained cells.
doi:10.1371/journal.pone.0108414.g001
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t =27.97, p,0.0001, CI 20.304 to 20.142). NK cell monother-
apy treatment decreased ve compared to mAb9.2.29 (Scheffe,
t =24.22, p= 0.007, CI 20.293 to 20.534) and compared to
untreated controls (Scheffe, t = 3.83, p = 0.013, CI 0.482 to 0.357)
(Figure 5B). The difference in ve between NK+mAb9.2.27 and
mAb9.2.27 monotherapy was lost after increased dose of NK cells
(Figure 5B). Parametric maps of ve provided spatial information
about treatment effects on a voxel-by-voxel basis (see Figure 5A
and 5B), visualizing large intra-tumoural heterogeneity in the
interstitial volume fraction in the NK+mAb9.2.27 combination
therapy and control groups.
Estimated parameters for blood flow, permeability and
angiogenesis were not significantly affected by
treatment
MRI derived parameters reflecting the vessel function and vessel
wall integrity revealed less treatment dependent changes than the
parameter denoting the interstitial volume fraction. The transfer
constant Ktrans describes the flux from vessels to interstitium but no
effect of the treatment was found on Ktrans in any of the cohorts.
Furthermore, the model-independent parameter AUC1 min was
not significantly changed in any of the groups at any time point
(data not shown). Also, the parameter reflecting the blood plasma
fraction, vp, did not change significantly between groups.
Correspondingly, at end-stage histology, there was no significant
difference in the angiogenic capacity of the tumours (data not
shown).
Increased water diffusion associates with reduced
volume fraction in non-responsive animals
Diffusion properties of water molecules in tumour interstitium
was measured by DWI and expressed as ADC, which was
increased in all tumours compared to normal brain tissue, most
likely induced by perivascular oedema. However, mean ADC did
not change significantly over time in any group and was not
significantly different between the groups either. When performing
correlation analysis of ADC values with DCE derived parameters,
we could not find any overall association between ADC and Ktrans,
ve or AUC1 min. However, for animals treated with the NK+
mAb9.2.27 combination treatment and NK cell monotherapy,
there was a significant association between ADC and ve
(R2 = 0.798, p= 0.041 and R2= 0.993, p = 0.004, Figure 5C).
Interestingly, for both groups, an increased ADC value was
associated with a reduction in ve. No associations were observed
between ADC and extracellular volume fraction in control animals
and animals treated with mAb9.2.27 alone.
Discussion
The strategy of targeting the NG2/CSPG4 proteoglycan with
monoclonal antibodies in combination with the ADCC killing and
cytokine modulating effect of NK cells proved to have the greatest
therapeutic effect, compared to mAb9.2.27 or NK cell monother-
apies. Therapeutic efficacy was validated at earlier time points by
physiological MRI, and corroborated by histology and structural
MRI findings at later stages. Four out of seven animals (60%) in
the NK+mAb9.2.27 combination therapy group were alive at 3
months follow-up scans, whereas none were alive from the other
treatment groups [16]. The infused rat NK cells expressed CD16
[16], a low affinity Fcc-III receptor that binds antibody Fc
domains to mediate activating signals that stimulate NK cells to
kill coated target cells by ADCC. In our previous study we
demonstrated that microglia in the tumour microenvironment
were also able to bind the mAb9.2.27 via their Fc receptor to
mediate effective GBM killing ex vivo [16]. These mechanisms are
likely involved in the therapeutic efficacy of the combination
treatment also in the present study. Nevertheless, we report herein
that NK cell monotherapy failed to control GBM. The interstitial
volume fraction, denoted by the MRI parameter ve, indicated that
NK cell monotherapy failed to reduce the tumour cellular burden
in the tumour microenvironment and this was corroborated by
histological measures of decreased apoptosis, increased cell
proliferation and subsequently, the poor survival outcomes of
these animals [16]. This might be due to U87MG tumour cells’
expression of elevated levels of class I HLA and non-classical HLA
ligands for inhibitory receptors that supress NK cell activation
against the tumour cells, as well as diminished expression of stress
induced ligands for activating NK cell receptors. Although the
HLA gene locus is highly pleomorphic with regard to gene content
and allelic polymorphisms, the classical class I regions in humans,
mice, and rats are relatively conserved. Nude rats express Ly-49
Table 1. U87MG tumour cells’ expression of glial markers and ligands for NK cell receptors.
Marker % cells MFI
HLA-ABC 97,4 6049
HLA-DR,DP,DQ 33,7 172
HLA-E 1,19 377
HLA-G 14 11,3
MICA 7,99 99,1
MICB 0 -
ULBP-1 40,4 2721
ULBP-2-5-6 95,9 12979
ULBP-3 94,6 7421
A2B5 10 637
Nestin 96,5 2208
Vimentin 88 2154
GFAP 97,3 397
doi:10.1371/journal.pone.0108414.t001
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molecules [32] that recognize RT1-A, rodent orthologues to killer
immunoglobulin like receptors (KIRs) and class I HLA (respec-
tively), in humans. Given the low alloreactivity of the rat NK cells
to the human GBM cells, we interpret that dominant inhibitory
signals might have been transduced when rodent Ly-49 recognized
the class I HLA ligands on U87MG cells, in addition to the non-
classical HLA-G and HLA-E, in the absence of NKG2D
dependent activation signals.
T1-weighted post-contrast images at 3 months and histological
analyses revealed a regression of the NK+mAb9.2.27 combination
treated tumours. Lack of contrast enhancement at the tumour
region at this time point demonstrated treatment efficacy as
confirmed by the diminished tumour tissue on histological
staining. In our separate study, survival analyses demonstrated a
correlation of NK+mAb9.2.27 treatment with prolonged survival
in several tumour models [16].
There is currently a pressing need for imaging biomarkers that
provide information about the tumour phenotypes in response to
immunotherapy when it comes to tumour cell density, cell death
and tumour-stromal tissue architecture. Changes in physiological
parameters that correlate with therapeutic efficacy may be
detected earlier in the treatment process than gross morphological
changes such as tumour size. The findings reported in this study
supported this hypothesis. We observed larger tumour lesions on
contrast enhanced T1-weighted structural MR images after
immunotherapy despite prolonged survival. This phenomenon
may reflect genuine tumour progression or alternatively, it may be
due to recruitment of immune cells into the tumour from the
peripheral circulation. Indeed we recorded greater tumour
infiltration by microglia/macrophages with pro-inflammatory
phenotypes after combination NK+mAb9.2.27 compared to
monotherapy and control animals at early stages [16] as well as
at end-stage in the present study. Since the combination NK+
mAb9.2.27 treatment diminished tumour growth index and
prolonged survival, the contradictory increase in contrast en-
hancement might represent a false progression due to inflamma-
tory processes. The increased contrast enhancement might be
caused by a pronounced local tissue reaction with an inflammatory
component, edema, and abnormal vessel permeability causing
increased leakage of the contrast agent, and is most likely similar to
the so-called flare effect, previously reported following immuno-
therapy with intralesionally infused lymphocytes in patients with
recurrent high grade astrocytomas [33]. The flare effect is
characterized by apparent worsening of the lesion in MRI images
shortly after immunotherapy exhibiting increased nodular en-
hancement, increased oedema, and mass effect that resolves by 3
months in patients. Interestingly, we observed at the 3-month
follow-up that the increased enhancement had resolved, with no
further tumour recurrence in the NK+mAb9.2.27 treated animals.
The flare effect was also reported following gene therapy [34],
convection enhancement delivery of cytokines [35] or after
placement of the GliaSite radiation therapy system [36] to treat
brain tumour patients. This validates our findings that following
immunotherapy, longitudinal multiparametric MRI should be
Figure 2. Longitudinal T1-weighted images and tumour
growth. (A) Longitudinal axial post-contrast T1-weighted images of
nude rats bearing U87MG tumours treated with combination NK+
mAb9.2.27, NK cell monotherapy, mAb9.2.27 monotherapy, and vehicle
controls, showing the same animal after 7 days, 17 days and 3 months
post NK+mAb9.2.27 treatment. (B) Tumour volumes (#voxels) quanti-
fied on post-contrast T1-weighted images, before and after 7 and 17
days treatment. Data represents mean 6SEM of all animals treated.
doi:10.1371/journal.pone.0108414.g002
Figure 3. Longitudinal T2-weighted images. Longitudinal corre-
sponding axial T2-weighted images of same animals as in Figure 2.
Nude rats bearing U87MG tumours treated with combination NK+
mAb9.2.27, NK cell monotherapy, mAb9.2.27 monotherapy, and vehicle
controls, showing the same animal after 7 days, 17 days and 3 months
post NK+mAb9.2.27 treatment.
doi:10.1371/journal.pone.0108414.g003
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performed to delineate whether the apparent increase of tumour
enhancement and region of interest is due to the flare effect or to
real tumour progression. Several papers point out this limitation of
the RANO or Macdonald’s radiological response criteria for
immunotherapy [37] [5] [4] that use the enhancing tumour area
as the primary measure of response, without considering the
patients’ use of steroids and changes in their neurologic status [38].
Tumour enhancement can occur following a variety of non-
tumoural processes such as inflammation, seizure activity,
postsurgical changes, and radiation necrosis [39–42]. Although
the established criteria have limitations, in addition to the
particular difficulty of measuring the often irregular shape of
diffusely infiltrative gliomas, they are nevertheless widely accepted.
Here we have demonstrated that longitudinal physiological MR
imaging provided more sensitive quantitative measures that
allowed us to characterize tumour progression longitudinally.
The derived parameter ve, that describes the volume fraction of
the interstitium, proved to change earlier in the treatment process
than the tumour volume, and may provide important information
about the treatment course when traditional measures such as
Figure 4. Immunohistochemical staining and cell proliferation. (A, top panel) haematoxylin and eosin staining showing leucocyte packed
necrosis in U87MG tumours treated with NK+mAb9.2.27 and mAb9.2.27 monotherapy, (arrows), Magnification 200X; Scale bar 100 mm. Cellular dense
tumours treated with NK cell monotherapy and haemorrhaging control, untreated tumours. (A, middle panel) Ki67 staining of proliferating tumour
cells (A, bottom panel). Magnification 200X; scale bar 100 mm. Tunel stained apoptotic cells, Magnification 200X; Scale bar 100 mm. (B) Quantified
Ki67 labelling index, data represents mean 6SEM of all animals treated. (C) Quantified Tunel labelling index, data represents mean 6SEM of all
animals treated,*p,0.05; **p,0.001, ***p,0.0001. D Ratio of proliferation: apoptosis index.
doi:10.1371/journal.pone.0108414.g004
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tumour volume fail. Others have also suggested this parameter as a
candidate biomarker for the EES [43]. The volume fraction
increased after NK+mAb9.2.27 treatment compared to the
monotherapy and no treatment groups, despite adding more
NK cells into the lesion. The increased extracellular extravascular
space was due to augmented tumour cell death and reduced
cellular proliferation as indicated by the diminished growth index
on histological measures. Increased ve in the combination treated
animals thus correlated with efficient killing effect. Animals treated
with NK cell monotherapy exhibited the greatest growth index,
and ve was decreased. The reduction was more pronounced in
cohort 2 treated animal that received 2 million NK cells,
indicating a dose dependent response. This can most likely be
attributed to the presence of NK cells, in addition to the highly
cellular tumour mass contributing to a tightly packed tumour cell
mass, indicated also by histology. Thus, the volume of the
interstitial space was reduced. The killing efficacy of NK cells
alone was not sufficient to counteract the increase in cell numbers
in the solid tumour mass, leading to reduced volume of interstitial
space. This illustrates that mAb9.2.27 bound to the NG2/CSPG4
positive tumour cells was required to trigger ADCC mediated
cytotoxicity and facilitate the efficacy of NK cells in this GBM
model. The reduced interstitial volume fraction in the NK cell
monotherapy group was accompanied by a tendency of reduction
in the transvascular transport (Ktrans) and initial contrast uptake
(AUC1 min). However, mechanical forces within the solid tumour
play a role. Proliferating tumour cells induce physical stress that
compresses blood vessels and therefore reduce the blood flow.
Also, as a result of vessel leakiness and lack of functional
lymphatics in most solid tumours, interstitial fluid pressure is
significantly elevated, which is more profound in the inferior of the
tumour [44], [45,46]. As convection is one of the driving
mechanisms of transvascular fluid transport, high interstitial
pressure will work against efflux of fluid from the vessels, which
in our study was reflected as reduced Ktrans and AUC1 min. The
estimated Ktrans may also be influenced by blood flow and not
exclusively by permeability when using low-molecular weight
contrast agents [24,47,48]. This assumption complicates the
interpretation of this parameter, and may explain why Ktrans did
not give any indication of treatment course in any of the groups.
The increased extracellular volume fraction expressed as ve, in
the control tumours may be due to de novo necrosis caused by
reduced blood supply, followed by hypoxia and cell death in the
central parts of the tumour [29,49]. This corresponds well with the
Figure 5. Perfusion parameters and maps. (A) Elevated extravascular extracellular volume fraction ve, in NK+mAb9.2.27 compared to
monotherapy animals from cohort 1 (received 1 million NK cells), *p,0.05, **p,0.001 ***p,0.0001. (A left panels) Parametric maps visualising
intratumoral heterogeneity in ve in representative control, monotherapy and NK+mAb9.2.27 treated animals at 7 days. Intensity scale shows
minimum (blue voxels) and maximum (red voxels) intensity levels. (B) Increased interstitial extracellular volume fraction, ve, elevated in NK+
mAb9.2.27 compared to NK cells and mAb9.2.27 monotherapy animals, and decreased ve in NK cell monotherapy compared to untreated control
from cohort 2 (treated with 2 million NK cells), *p,0.05, **p,0.001, ***p,0.0001. (B, left panels) Parametric maps visualising intratumoural
heterogeneity in ve in control, monotherapy and NK+mAb9.2.27 treated animals at 17 days. (C) Significant association between ADC and ve in the
NK+mAb9.2.27 (R2 = 0.798, p = 0.041) and NK cell monotherapy animals (R2 = 0.993, p = 0.004). Graphs in A and B represent estimated marginal
mean695% confidence intervals.
doi:10.1371/journal.pone.0108414.g005
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histological analyses and the parametric maps of ve and similar to
other studies, where increasing ve with increasing brain tumour
grade has been reported [50]. The lack of significance in the
estimated plasma volume vp might be due to the fact that we used
a literature based arterial input function (AIF) as baseline for the
analyses. Ideally, AIF should be individually measured since vp is
highly dependent on the chosen AIF. However, all animals
received a dose of the contrast agent dependent on the individual
body weight, and the same injection time and speed were used, so
inter-individual differences in the AIF were kept at the minimum.
Also, inflow effects and slice positioning may influence the
measured individual AIF and interfere with the result. An
alternative explanation in the lack of differences in the plasma
volume, is that the mAb9.2.27 is highly specific for the human
CSPG4 epitope. Thus mAb9.2.27 monotherapy did not exhibit
anti-angiogenic effects against the rat NG2 expressing tumour
vessels. Indeed, no difference in microvascular densities as a
measure of angiogenesis was demonstrated on immunohistochem-
istry.
ADC represents the random diffusion of water molecules within
tissues and has been shown to be inversely correlated with tumour
cell density [51]. ADC has furthermore been linked to cell death
following treatment [52]. In this study we could not detect
statistically significant changes in the estimated ADC value over
time as a response to treatment. This is most likely due to the
impact of other determinants of water diffusivity within the
complex microenvironment encountered in gliomas. The presence
of necrosis is an important diagnostic criterion for GBM that
distinguishes this aggressive tumour from the low-grade tumours.
The necrotic tissue may manifest as mobile fatty acid lipid moieties
that are not associated with membrane phospholipids. Necrotic
cell debris and deposits of blood after local haemorrhage are all
factors that hinder the free movement of water molecules in the
EES [43]. The ADC value is a fraction of both intra-cellular and
extra-cellular diffusion [30] and is affected by not only the cellular
density but also tissue tortuosity, extracellular components and
their organization [53]. Additionally, intracellular diffusion and
membrane permeability impact free movement of water and thus
ADC. The ADC value was not affected by tumour size per se but
highly dependent on the altered microarchitecture and physiology
that characterize a malignant tumour.
Consistent with this, we found a statistically significant negative
association between the ADC value and ve in the NK+mAb9.2.27
combination therapy and NK cell monotherapy group, where high
ve values corresponded with low ADC values. This indicates that
the ADC value and ve may reflect different aspects of the tumour
microenvironment and the ADC value may be more complex than
simply reflecting the volume of the interstitial space. Our findings
are supported by others [54] and [43]. In patients with glioma, no
correlation between ADC and ve was found and the authors
suggested that the interpretation of these parameters is over
simplified [43]. A negative correlation of ADC and ve in breast
tumour patients was reported [54]. However, they found that the
ADC value was a better predictor of tumour response of
chemotherapy than ve in these patients. The ADC value is not
only dependent on the volume of the EES but also the composition
of the EES. Tumours are composed of the malignant cell
compartment and the ‘‘benign’’ stromal cell compartment that
includes blood vessels, infiltrating inflammatory cells, extracellular
matrix, and stromal fibroblasts. The precise composition of the
tumour microenvironment varies depending on the tumour site
and histology. The brain, in particular, consists of numerous
specialized cell types such as glia, brain endothelial cells and a
relative paucity of extracellular matrix components. Therefore, the
biological interpretation of the estimated MR-based parameters
may vary between tumours of different histological origin, thus the
tumour specific and treatment dependent physiology must always
be taken into consideration. Other groups also failed to find a
correlation between cell density and ADC in gliomas [55]. This
corroborates our lack of correlation between ve and ‘‘tumour size’’
at these early time points (3 weeks post treatment). This may be
attributed to the high intra-tumour heterogeneity of GBMs with
areas of oedema and cyst formation, vascular proliferation and
necrosis, that all influence the estimated ADC value in numerous
ways [43]. Also, the b-values have an impact on the ADC, as
higher b-values (above 1000 s/mm2) weight the intracellular part
of the ADC value more than lower b-values. The magnitude,
duration, and temporal duration of the diffusion gradients
determine the b-value and influence the signal observed in the
DW images [43]. Several studies have concluded with that higher
b-values (b = 3000 s/mm2) were more useful in discriminating
low-grade and high-grade gliomas [56,57] and to also discriminate
true progression from pseudoprogression in patients with GBM
undergoing radiation therapy and concomitant temozolomide
[58].
To our knowledge, we are the first to report longitudinal and
simultaneous measurements of both ADC and ve in GBMs in the
same animals. Being aware of the limited number of animals
included in the study, our results indicate that ve might be a
reliable parameter for detecting early treatment response of
targeted immunotherapy in GBMs using combined NK +
mAb9.2.27. The ve parameter is often overseen and not reported
in many studies but may prove to be a candidate for the interstitial
volume as it is a direct measurement of the EES [24]. However,
the robustness of this parameter remains to be interrogated when
targeting other receptors with different antibodies, therapy
combinations, or mode of drug administration. More data will
be required to establish a predictive model for treatment response
based on MR derived physiological parameters. Utilisation of
histogram analyses may provide more detailed information about
tumour heterogeneity in GBMs.
Although, standard morphological MR imaging has played a
pivotal role in defining landmarks used to manage GBM clinically,
physiological MR imaging may hold the potential to improve
diagnosis, prognosis, and prediction for individual patients’
outcome in the long term. We have demonstrated that multi-
parametric longitudinal imaging provided a more comprehensive
portrait of the tumour’s microenvironment. Each MR sequence
added additional knowledge about the tumour’s response to
treatment and allowed studies of the inter-related physiological
parameters, which is a prerequisite for individualised treatment.
Targeted immunotherapy against the NG2/CSPG4 proteoglycan
in combination with the killing and cytokine modulating effect of
NK cells improved therapeutic effects as determined by MRI.
Supporting Information
Figure S1 Comparison of tumour infiltrating immune
cells after various treatments. (A) Cellular composites of
resident lymphocytes (CD45highCD11b/c low); macrophage/
microglia (CD45+CD11b/c+) in control, mAb9.2.27 only, NK cell
only and NK+mAb9.2.27 treated representative animals. (B) NK+
mAb9.2.27 treated animals had greatest proportions of microglia
that were similar to those in normal brain. The microglia were
ED1+CD8+ and expressed MHC-class II molecules indicating an
activated capable of antigen presentation. (C) Double staining for
CD8 (brown) and ED1 (red) in histological tissues showing tumour
infiltrating ED1/CD8+macrophage/microglia, greatest infiltration
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in NK+mAb9.2.27 treated tumours. Arrows in panel C indicate
tumour region, Magnification 200X, scale bar 100 mm. Data
corroborates flow cytometric findings presented in panels A and B.
(TIF)
Materials and Methods S1 Supporting Materials and
Methods.
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